Objective: To investigate the antibacterial effect of baicalin combined with cefoperazone-sulbactam sodium on drug-resistant strains of Pseudomonas aeruginosa. Method: Pseudomonas aeruginosa strains that are sensitive and resistant to cefoperazone-sulbactam sodium were selected to prepare different test bacterial solutions respectively; The test solutions of baicalin and cefoperazone sulbactam sodium were prepared respectively, and different test groups and control groups were set up; The drug sensitivity tests of different concentration gradients of baicalin and cefoperazone sulbactam sodium used alone and in combination were carried out for different sensitive and drug-resistant strains, and the standard strains were used as parallel control. Result: The drug susceptibility test results of the combined use of baicalin and cefoperazone-sulbactam against Pseudomonas aeruginosa drug-resistant strains were compared with the drug susceptibility results of the two used separately, and the difference was statistically significant (P < 0.05); The combined effect of the two was dependent on strain and concentration. Conclusion: The combined use of baicalin and cefoperazone-sulbactam sodium has a certain synergistic bacteriostatic or bactericidal effect on drug-resistant strains of Pseudomonas aeruginosa.
References
[1]
Yu, Y., Shao, X.S., Yang, W.P., et al. (2018) Clinical Distribution and Drug Resistance of Pseudomonas aeruginosa in a Tertiary Hospital. Chinese Journal of Disinfection, 35, 63-66.
[2]
Liu, Y., Wang, M.Q., Zhu, B.T., et al. (2019) Drug Resistance Analysis and Homology Study of Pseudomonas aeruginosa in Packaged Drinking Water. China Brewing, 6, 132-135.
[3]
Wagner, S., Sommer, R., Hinsberger, S., et al. (2016) Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections. Journal of Medicinal Chemistry, 59, 5929-5969. https://doi.org/10.1021/acs.jmedchem.5b01698
[4]
Valentini, M. and Filloux, A. (2016) Biofilms and c-di-GMP Signaling: Lessons from Pseudomonas aeruginosa and Other Bacteria. Journal of Biological Chemistry, 291, 12547-12555. https://doi.org/10.1074/jbc.R115.711507
[5]
Weinstein, M.P. and Lewis, J.S. (2020) The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing: Background, Organization, Functions, and Processes. Journal of Clinical Microbiology, 58, e01864-19. https://doi.org/10.1128/JCM.01864-19
[6]
Shang, H., Wang, Y.S. and Shen, Z.Y. (2015) National Clinical Testing Operational Regulations. People’s Health Publishing House, Beijing, 11-50.
[7]
Humphries, R., Bobenchik, A.M., Hindler, J.A. and Schuetz, A.N. (2021) Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition. Journal of Clinical Microbiology, 59, e0021321. https://doi.org/10.1128/JCM.00213-21
[8]
Zhang, P., Guo, Q., Wei, Z., et al. (2021) Baicalin Represses Type Three Secretion System of Pseudomonas aeruginosa through PQS System. Molecules, 26, 1497. https://doi.org/10.3390/molecules26061497
[9]
Luo, J., Dong, B., Wang, K., et al. (2017) Baicalin Inhibits Biofilm Formation, Attenuates the Quorum Sensing-Controlled Virulence and Enhances Pseudomonas aeruginosa Clearance in a Mouse Peritoneal Implant Infection Model. PLoS ONE, 12, e0176883. https://doi.org/10.1371/journal.pone.0176883
[10]
Zhou, X.L., Sun, X.X., Yan, J., et al. (2005) Antibacterial Activity of Cefoperazone Sulbactam against Pseudomonas aeruginosa. Chinese Journal of Anti-Infective Chemotherapy, No. 1, 44-45.
[11]
Cui, Y.X. (2003) Analysis of Drug Resistance of Cefoperazone/Sulbactam and Other Antibiotics to Various Types of Pseudomonas aeruginosa. Henan Journal of Oncology, No. 4, 300-301.
[12]
Dong, B.Y. (2016) Baicalein Inhibits the Motility of Pseudomonas aeruginosa and the Synergistic Effect of Cefoperazone/Sulbactam on Its Biofilm in Vitro. Guangxi Medical University, Nanning.
[13]
Dong, B.Y., Chen, Y.Q., Kong, J.L., et al. (2016) In Vitro Study of Baicalin Combined with Cefoperazone/Sulbactam on the Destruction of Pseudomonas aeruginosa Biofilm. Chinese Journal of Modern Medicine, 18, 1-4.
[14]
Bayot, M.L. and Bragg, B.N. (2020) Antimicrobial Susceptibility Testing.
Arakawa, Y., et al. (2000) Convenient Test for Screening Metallo-β-Lactamase-Producing Gram-Negative Bacteria by Using Thiol Compounds. Journal of Clinical Microbiology, 38, 40-43. https://doi.org/10.1128/JCM.38.1.40-43.2000
[17]
Li, S.H., Li, D., Yu, F.M., et al. (2017) In Vitro Antibacterial Activity of Cefoperazone/Sulbactam against Acinetobacter baumannii and Klebsiella pneumoniae. Chinese Journal of Hospital Infectious Diseases, 27, 1452-1455.
[18]
Gong, M.L., Li, X.X., Zhou, Y., et al. (2016) Inhibition of Carbapenem-Resistant Acinetobacter baumannii in Combination with Etimicin and Cefoperazone/Sulbactam and Piperacillin/Tazobactam in Vitro Role. Journal of PLA Medical College, 37, 876-878.
[19]
Xu, A.X., Zeng, X., Hu, Y., et al. (2019) In Vitro Antibacterial Effects of Psyllium Extract and Cefoperazone Sodium/Sulbactam Sodium on ESBLs-Producing Escherichia coli. Jiangxi Medicine, 54, 1034-1036.
[20]
Wang, Q.M., Lu, D.Q., Peng, M., et al. (2019) Clinical Distribution and Drug Resistance Analysis of 2279 Strains of Pseudomonas aeruginosa for 5 Consecutive Years. Laboratory Medicine and Clinic, 16, 3437-3440.
[21]
Hoffman, L., D’Argenio, D., Maccoss, M., et al. (2005) Aminoglycoside Antibiotics Induce Bacterial Biofilm Formation. Nature, 436, 1171-1175. https://doi.org/10.1038/nature03912
[22]
Huang, X.H., Gao, G.Y. and Huang, Z.A. (2018) In Vitro Antibacterial Effects of 12 Traditional Chinese Medicines on 20 Strains of Extensively Drug-Resistant Pseudomonas aeruginosa. China Practical Medicine, 13, 196-198.
[23]
Zhou, X. and Zhou, B.J. (2017) In Vitro Antibacterial Activity of 113 Traditional Chinese Medicine Decoctions against Pseudomonas aeruginosa. Chinese Medicine Forum, No. 4, 59-61.
[24]
Xie, L.L., Zhou, M., Chen, Y.C., et al. (2010) Study on the Inhibition of Pseudomonas aeruginosa Biofilm Formation by Baicalin and Baicalein. China Pharmacy, 21, 3651-3653.
[25]
Jian, L.Y., He, X.J. and Yu, Y. (2012) Effects of Baicalin Combined with Levofloxacin on Pseudomonas aeruginosa Biofilm and Related Mechanisms. Chinese Journal of Hospital Pharmacy, 32, 1097-1099.
[26]
Cen, Y.L., Li, Y.N., Kong, J.L., et al. (2017) In Vivo Effects of Baicalin Combined with Meropenem on the Early Biofilm of Pseudomonas aeruginosa in the Peritoneal Cavity of Mice. Chinese Journal of Hospital Infection, 27, 39-42.
[27]
Lu, D.Y. and Lu, T.R. (2020) Drug Sensitivity Testing, a Unique Drug Selection Strategy. Advances in Biomarker Sciences and Technology, 2, 59-66. https://doi.org/10.1016/j.abst.2020.11.001
[28]
Yin, D., Wu, S., Yang, Y., Shi, Q., Dong, D., Zhu, D. and Hu, F. (2019) Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 63, e02431-18. https://doi.org/10.1128/AAC.02431-18
[29]
Olivares, P.J., Alvarez Ortega, C. and Luis, M.J. (2014) Metabolic Compensation of Fitness Costs Associated with Over-Expression of the Multidrug Efflux Pump MexEF-OprN in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 58, 3904-3913. https://doi.org/10.1128/AAC.00121-14
[30]
Topka-Bielecka, G., Dydecka, A., Necel, A., et al. (2021) Bacteriophage-Derived Depolymerases against Bacterial Biofilm. Antibiotics, 10, 175. https://doi.org/10.3390/antibiotics10020175
[31]
Xu, H.Y., Wang, S.F., Wang, L. and Wang, H. (2013) Study on the Antibacterial Effect of Shuanghuanglian Oral Liquid Combined with Gentamicin in Vitro. Medicine Herald, 32, 19-22.
[32]
Wang, L.J., Zeng, J.M., Lu, Y., Lan, K., Luo, Q., Lin, D.L., Zhang, W.Z. and Chen, C. (2017) Study on the Effect of Traditional Chinese Medicine on the Efflux Pump of Multidrug-Resistant Pseudomonas aeruginosa. Journal of Molecular Diagnosis and Therapy, 9, 401-407.
[33]
Ionescu, C.M., Ghita, M., Copot, D., et al. (2020) A Minimal PKPD Interaction Model for Evaluating Synergy Effects of Combined NSCLC Therapies. Journal of Clinical Medicine, 9, 1832. https://doi.org/10.3390/jcm9061832
